Application of Pathological Staging in Esophageal Squamous Cell Carcinoma

  • Alfred K. LamEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2129)


Pathological staging is the most important factor that determines the prognosis and management of patients with esophageal squamous cell carcinoma. The method for the pathological staging in esophageal squamous cell carcinoma involves assessment of standard parameters—extent of tumor (T), lymph node status (N), presence of distant metastasis (M), as well as grade (G) and anatomical location of the carcinoma. In addition, other relevant factors, such as use of neoadjuvant therapy, could affect the pathological staging of esophageal squamous cell carcinoma.

Key words

Esophageal Squamous carcinoma Staging Pathology Neoadjuvant therapy 


  1. 1.
    Lam AK (2018) Application of pathological staging in esophageal adenocarcinoma. Methods Mol Biol 1756:93–103CrossRefGoogle Scholar
  2. 2.
    (2010) Esophagus and Esophagogastric junction. In: Chapter 10: AJCC cancer staging manual, 7th. edn, Part 3. Springer, New York, pp p103–p155Google Scholar
  3. 3.
    Rice TW, Blackstone EH, Rusch VW (2010) 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol 17:1721–1724CrossRefGoogle Scholar
  4. 4.
    Rice TW, Kelsen D, Blackstone E, Ishwaran H, Patil DT, Bass AJ, Erasmus JJ, Gerdes H, Hofstetter WL (2016) Esophagus and Esophagogastric junction. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (eds) Chapter 16: AJCC cancer staging manual, 8th edn. Springer, New York, pp 185–202Google Scholar
  5. 5.
    D'Journo XB (2018) Clinical implication of the innovations of the 8(th) edition of the TNM classification for esophageal and esophago-gastric cancer. J Thorac Dis 10:S2671–S2681CrossRefGoogle Scholar
  6. 6.
    Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Hofstetter WL, Watson TJ, Allen MS, Rusch VW, Blackstone EH (2010) Optimum lymphadenectomy for esophageal cancer. Ann Surg 251:46–50CrossRefGoogle Scholar
  7. 7.
    Chen YJ, Schultheiss TE, Wong JY, Kernstine KH (2009) Impact of the number of resected and involved lymph nodes on esophageal cancer survival. J Surg Oncol 100:127–132CrossRefGoogle Scholar
  8. 8.
    Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Hölscher A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR (2008) The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 248:549–556CrossRefGoogle Scholar
  9. 9.
    Rice TW, Ishwaran H, Hofstetter WL, Schipper PH, Kesler KA, Law S, Lerut EM, Denlinger CE, Salo JA, Scott WJ, Watson TJ, Allen MS, Chen LQ, Rusch VW Cerfolio RJ, Luketich JD, Duranceau A, Darling GE, Pera M, Apperson-Hansen C, Blackstone EH (2017) Esophageal cancer: associations with (pN+) lymph node metastases. Ann Surg 265:122–129CrossRefGoogle Scholar
  10. 10.
    Brown IS, Fujii S, Kawachi H, Lam AK, Saito T Oesophageal squamous cell carcinoma NOS. In: Odze RD, Lam AK, Ochiai A, Washington MK (eds) Chapter 2: WHO classification of tumours, 5th edn, pp 48–53Google Scholar
  11. 11.
    Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P (2017) Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol 12:36–42CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Cancer Molecular Pathology of School of MedicineGriffith UniversityGold CoastAustralia

Personalised recommendations